Dr Luciano Costa speaks to ecancer at ASCO 2024 about results from the subgroup analysis from the CARTITUDE-4 study, which evaluated ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma.
He explians that in the initial analysis, a single ciltacabtagene autoleucel infusion significantly improved progression-free survival vs established standard of care.
Dr Costa reports that in patients with len-refractory FHR MM after 1 prior line of treatment, ciltacabtagene autoleucel improved outcomes vs standard of care.